MorphoSys Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Jean-Paul Kress

Chief executive officer

€4.8m

Total compensation

CEO salary percentage	18.1%
CEO tenure	4.6yrs
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	7.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jean-Paul Kress's remuneration changed compared to MorphoSys's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	€5m	€864k	-€190m
Sep 30 2023	n/a	n/a	€91m
Jun 30 2023	n/a	n/a	€88m
Mar 31 2023	n/a	n/a	-€73m
Dec 31 2022	€5m	€797k	-€151m
Sep 30 2022	n/a	n/a	-€861m
Jun 30 2022	n/a	n/a	-€851m
Mar 31 2022	n/a	n/a	-€596m
Dec 31 2021	€2m	€770k	-€514m
Sep 30 2021	n/a	n/a	-€150m
Jun 30 2021	n/a	n/a	-€103m
Mar 31 2021	n/a	n/a	-€177m
Dec 31 2020	€3m	€723k	€98m
Sep 30 2020	n/a	n/a	€64m
Jun 30 2020	n/a	n/a	€105m
Mar 31 2020	n/a	n/a	€153m
Dec 31 2019	€4m	€233k	-€103m

Compensation vs Market: Jean-Paul's total compensation ($USD5.10M) is above average for companies of similar size in the UK market ($USD2.58M).

Compensation vs Earnings: Jean-Paul's compensation has been consistent with company performance over the past year.

CEO

Jean-Paul Kress (58 yo)

4.6yrs

Tenure

€4,764,900

Compensation

Dr. Jean-Paul Kress, M.D. has been the Chief Executive Officer of MorphoSys AG since September 1, 2019 and has been its Management Board Member since 2019 and serves as its Chairman of Management Board and...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jean-Paul Kress	Chairman of Management Board	4.6yrs	€4.76m	no data
Lucinda Crabtree	CFO & Member of Management Board	1.3yrs	€1.51m	no data
Charlotte Lohmann	Chief Legal and Human Resources Officer & Member of Management Board	4.3yrs	€1.10m	0.0036% € 91.7k
Klaus De Wall	Head of Accounting & Tax	no data	no data	no data
Margit Urban	Head of Discovery Alliances & Technologies	no data	no data	no data
Julia Neugebauer	Head of Investor Relations	no data	no data	no data
Barbara Krebs-Pohl	Chief Business Officer	no data	no data	no data
Günter Wellnhofer	Head of Technical Operations	no data	no data	no data
Harald Watzka	Head of Alliance Management	no data	no data	no data
Yen Ching Chua	Head of Clinical Operations	no data	no data	no data
Kathrin Tissot	Head of Business Team	no data	no data	no data
Thomas Biegi	Senior VP & Head of Corporate Affairs	less than a year	no data	no data

2.8yrs

Average Tenure

53yo

Average Age

Experienced Management: MORD's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Brosnan	Independent Member of the Supervisory Board	5.9yrs	€116.90k	0.013% € 339.4k
Marc Cluzel	Independent Chairman of the Supervisory Board	11.9yrs	€160.20k	0.023% € 578.5k
Andrew Cheng	Independent Member of Supervisory Board	1.9yrs	€80.10k	no data
Bruce Cheson	Member of Scientific Advisory Board	7.6yrs	no data	no data
George Golumbeski	Independent Deputy Chairman of Supervisory Board	5.9yrs	€100.10k	no data
Gunther Adolf	Member of Scientific Advisory Board	7.6yrs	no data	no data
Sergio Quezada	Member of Scientific Advisory Board	7.6yrs	no data	no data
Raymond Sweet	Member of Scientific Advisory Board	7.6yrs	no data	no data
Krisja Vermeylen	Independent Member of the Supervisory Board	6.9yrs	€96.50k	0.0080% € 203.7k
Sharon Curran	Independent Member of Supervisory Board	4.8yrs	€92.60k	no data

7.3yrs

Average Tenure

61yo

Average Age

Experienced Board: MORD's board of directors are considered experienced (7.3 years average tenure).

MorphoSys Management

Management criteria checks 3/4

Key information

Recent management updates

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

MorphoSys AG Announces Executive Changes

MorphoSys AG Announces Supervisory Board Changes

MorphoSys AG Announces Management Changes

MorphoSys AG, Annual General Meeting, May 19, 2021

MorphoSys Appoints Thomas Biegi as Vice President, Head of Corporate Communications

Recent updates

Investor sentiment improves as stock rises 69%

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

Novartis data42 AG entered into an agreement to make a voluntary public takeover offer to acquire MorphoSys AG (XTRA:MOR) for €2.3 billion.

MorphoSys AG Provides Sales Guidance for the Financial Year 2024

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 70%

MorphoSys AG to Report First Half, 2024 Results on Aug 07, 2024

MorphoSys AG has filed a Follow-on Equity Offering in the amount of €102.69582 million.

MorphoSys AG to Report Fiscal Year 2023 Results on Mar 13, 2024

MorphoSys AG’ Pelabresib Improves All Four Hallmarks of Myelofibrosis in Phase 3 MANIFEST-2 Study

MorphoSys AG Announces Strong Topline Results from the Phase 3 MANIFEST-2 Study Investigating Pelabresib

New major risk - Financial position

Third quarter 2023 earnings released: €3.50 loss per share (vs €3.60 loss in 3Q 2022)

Investor sentiment improves as stock rises 27%

MorphoSys AG to Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting

Morphosys AG Provides Earnings Guidance for the Year 2023

Investor sentiment deteriorates as stock falls 15%

Zoetis Inc. (NYSE:ZTS) acquired adivo GmbH from founders, High-Tech Gründerfonds, the Swiss Occident Group AG and MorphoSys AG (XTRA:MOR).

Investor sentiment improves as stock rises 16%

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: €2.16 loss per share (vs €6.88 loss in 2Q 2022)

MorphoSys AG Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings released: €1.30 loss per share (vs €3.59 loss in 1Q 2022)

Morphosys Ag Provides Sales Guidance for the Financial Year 2023

Full year 2022 earnings released: €4.42 loss per share (vs €15.40 loss in FY 2021)

MorphoSys AG Expects Topline Data from Phase 3 Study of Pelabresib in Myelofibrosis in Early 2024

MorphoSys AG Announces Sung Lee, Chief Financial Officer Decided to Leave

Morphosys Presents New Longer-Term Phase 2 Results on Pelabresib in Myelofibrosis, Including Potential Disease-Modifying Activity At Ash 2022

MorphoSys AG to Report Q3, 2023 Results on Nov 15, 2023

Third quarter 2022 earnings released: €3.60 loss per share (vs €3.30 loss in 3Q 2021)

MorphoSys AG Presents Preliminary Results from Phase 1/2 Study of Tulmimetostat (CPI-0209)

Morphosys Ag Revises Monjuvi U.S. Net Product Sales Guidance for the Full Year of 2022

MorphoSys AG Announces Executive Changes

Morphosys Ag Updates Monjuvi U.S. Net Product Sales Guidance for the Year 2022

MorphoSys AG Confirms Financial Guidance for the Year 2022

MorphoSys AG Announces Supervisory Board Changes

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

MorphoSys Presents Latest Data from the Phase 2 Manifest Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis

MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Third quarter 2021 earnings released: €3.30 loss per share (vs €2.00 loss in 3Q 2020)

Health Canada Grants Marketing Authorization for Minjuvi® (Tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Second quarter 2021 earnings released: EPS €0.64 (vs €1.62 loss in 2Q 2020)

MorphoSys AG (XTRA:MOR) completed the acquisition of Constellation Pharmaceuticals, Inc. (NasdaqGS:CNST).

Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

MorphoSys to Present Data on Tafasitamab (Monjuvi(R)) at the 2021 ASCO Annual Meeting

Incyte and MorphoSys Announce First Patient Dosed in Phase 3 frontMIND Study Evaluating Tafasitamab Combination as a First-Line Treatment for Diffuse Large B-Cell Lymphoma

First quarter 2021 earnings released: €1.27 loss per share (vs €6.12 profit in 1Q 2020)

MorphoSys AG Reaffirms Group Financial Guidance for the Year 2021

Full year 2020 earnings released: EPS €3.01 (vs €3.26 loss in FY 2019)

New 90-day low: €88.08

New 90-day high: €101

I-Mab and MorphoSys Announce First Patient Dosed in U.S. Phase 1 Study of TJ210/MOR210 in Patients with Advanced Cancer

Incyte Corporation and MorphoSys AG Announce Acceptance by Health Canada of the New Drug Submission for Tafasitamab

New 90-day high: €99.36

MorphoSys AG Announces Management Changes

Morphosys and Incyte Announce the Acceptance of the Swissmedic Marketing Authorization Application for Tafasitamab

MorphoSys AG, Annual General Meeting, May 19, 2021

Incyte and MorphoSys AG Announces Data Evaluating Tafasitamab with and Without Lenalidomide in Combination with R-CHOP in Patients with DLBCL Presented At ASH 2020

Morphosys' Licensee Announces Approval by the European Commission for Tremfya(R) (Guselkumab) for Treatment of Adults with Active Psoriatic Arthritis

MorphoSys Appoints Thomas Biegi as Vice President, Head of Corporate Communications

Xencor, MorphoSys AG and Incyte Enter into Global Development Collaboration for Tafasitamab in Combination with Plamotamab

MorphoSys to Present Data on Tafasitamab at the ASH Virtual Annual Meeting and Exposition

MorphoSys AG Raises Financial Guidance for the Financial Year 2020

Jens Holstein Decides to Step Down as Member of the Morphosys AG's Management Board, Effective December 31, 2020

MorphoSys AG and I-Mab Announce FDA Clearance of IND Application for MOR202/TJ202 in Patients with Advanced Cancer

CEO Compensation Analysis

CEO

Tenure